Ad
Monday, 24 July 2017
U.S. jury finds AbbVie liable for misrepresentation in first AndroGel verdict
NEW YORK (Reuters) - A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment